Loading…

Montagu, a private equity firm, has acquired a majority stake in HTL, a pharmaceutical-grade biopolymer manufacturer, from Bridgepoint. Naxicap and Téthys Invest retain their minority shares.
“HTL embodies all the characteristics of a French industrial success and perfectly represents the kind of high-potential healthcare companies at the heart of our investment strategy.”montagu.com
Summarized from public sources; check the original articles before acting on it.